Semaglutide Linked to Fewer Asthma Attacks and COPD Exacerbations in UK Records

Semaglutide, the GLP-1 receptor agonist best known as a diabetes and obesity treatment, was linked to nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups in a real-world UK study presented at the European Respiratory Society (ERS) Congress in Barcelona this week. The semaglutide asthma attacks signal is early, drawn from health records and not yet peer-reviewed, and the authors stop well short of recommending the drug for respiratory disease. For market access teams, though, the abstract raises a question that will not settle quickly: whether fewer exacerbations could become a secondary value claim for a drug class still prescribed almost entirely for metabolic reasons.

What was presented

The analysis, led by Bohee Lee and senior author Chloe Bloom of the National Heart and Lung Institute at Imperial College London, ran four parallel new-user comparisons in UK electronic health records. Each arm compared people starting a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, or exenatide) against new users of sulfonylureas, with roughly 20,000 to 22,537 patients per comparison. An exacerbation was defined as an oral corticosteroid burst, an emergency department visit, a hospital admission, or death. The analyses used inverse-probability weighting and looked at both dose and the split between asthma and COPD.

The semaglutide asthma attacks finding needs careful handling

The ERS press line, issued through EurekAlert on 7 September, gave the clean talking point: semaglutide was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD exacerbations. The result is encouraging for people who already qualify for a GLP-1 because of obesity or type 2 diabetes, but no one should start the drug for a lung condition alone, and the finding needs randomised controlled trials.

Ad

The more granular numbers in the trade press do not line up cleanly with 40%. MedPage Today reported that any GLP-1 against sulfonylurea carried a 14% lower exacerbation risk, with semaglutide at 30% overall, 38% in asthma, and 21% in COPD. Exenatide came in at 23% and dulaglutide at 12%, while liraglutide and lixisenatide were not significant. HCPLive reported weighted hazard ratios: 0.76 for semaglutide overall (95% CI 0.60 to 0.96), with 0.75 for the low dose (0.58 to 0.95) and 0.28 for medium and high doses (0.08 to 1.01, an interval that crosses 1). For asthma the weighted hazard ratio was 0.20 (0.05 to 0.78) and for COPD 0.76 (0.58 to 1.00). Other agents were not significant in that write-up. The asthma figure implies an 80% relative reduction, but the confidence interval is very wide.

Science Media Centre experts flagged that precision problem on the day. Marie Spreckley of Cambridge said the headline uses causal language the study design cannot support and that the asthma estimate is imprecise. Stephen Burgess noted that a semaglutide-only signal may simply reflect more data rather than a unique molecule. Samantha Walker of Asthma + Lung UK said the promise holds only for people who already have a metabolic indication.

What this means for value and access

For payers and HTA bodies, the indication stays metabolic. The door is closed on off-label respiratory initiation. The live question is whether exacerbation reduction becomes a secondary value claim for people who already meet obesity or type 2 diabetes criteria, particularly high-exacerbation asthma with obesity, where inhaled corticosteroids underperform.

Three issues will shape the dossier. First, agent heterogeneity. If only semaglutide and possibly exenatide move the airway endpoint, class-level HTA language becomes harder, and Novo Nordisk’s SELECT asthma post-hoc is the natural pairing. Lilly’s dual agonists are not in this ERS cut. Second, the outcome definition is already HTA-ready: oral corticosteroid bursts, emergency visits, admissions, and deaths are the same events that drive asthma and COPD budget-impact models in Portugal, Spain, and NICE appraisals. Third, the weight-independent signal is the fight. If later trials confirm a pulmonary effect that does not track kilos lost, that changes how obesity drugs are positioned against biologics in obese asthma, and how INFARMED, AEMPS, and NICE would score additional respiratory benefit on top of glycaemic and weight outcomes.

Source: EurekAlert news release, 7 September 2026.